Replies to post #98274 on Amarin Corp Plc (AMRN)

[HDGabor]

K-

As I know / see:

WAC ( wholesale acquisition cost ) now about the same for generic Lovaza and Vascepa

"WAC price $234/month (120 capsules); net price parity to omega-3 generics for most payers" [IR Pres. Nov 2016] and WAC is the gross price (I do not have any info about gL WAC)

Generic Lovaza is Tier 2 and Vascepa is Tier 4 ... I'm assuming generic Lovaza has the lower Tier rating because it lowers very high TG's more then Vascepa

Branded Lovaza has the same or worse (or no) Tier as V, meanwhile exactly the same effect on TG as generic L. T2 vs T4 more likely due to type of the drug [generic (L) vs branded (V)], than efficacy

Best,
G

[sts66]

Last year when I was researching new Part D plans for 2017 I posted about a very strange price discrepancy between V and GL - Medicare.gov searches show what you'll pay, and also show what the actual cost of each drug is - GL only costs ~ $98/mo in 2017, and I asked "how the heck is that possible given the price of API?" - nobody responded, and the question still stands. No way Teva is making a penny selling GL at that price, so why are they selling it at all, except to keep V from owning the O3 market? Given V patent protection, even if Teva wants to be first to market GV, it's going to take years before they get the chance, so keeping their O3 production/sales forces in place is costing them a lot of money, unless they think they can win in court and overturn a patent or two.